Canada markets closed

Microbix Biosystems Inc. (MBX.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.6900-0.0200 (-2.82%)
At close: 01:56PM EST
Full screen
Previous Close0.7100
Open0.7100
Bid0.6800 x 0
Ask0.6900 x 0
Day's Range0.6700 - 0.7100
52 Week Range0.4900 - 0.8700
Volume31,675
Avg. Volume87,093
Market Cap89.677M
Beta (5Y Monthly)N/A
PE Ratio (TTM)26.54
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateSep. 02, 1999
1y Target EstN/A
All
News
  • GlobeNewswire

    Microbix Receives $4.7 Million Order for Viral Transport Medium

    Follow-on Order from Government of Ontario Procurement AuthoritiesMISSISSAUGA, Ontario, Dec. 24, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces receipt of a follow-on order of C$ 4.7 million for its viral transport medium (generically known as “VTM” and branded “DxTM™” by Microbix). DxTM is a sample-collection device that is essential for PCR-based testing for viruses that cause COVID-19 disease. This furth

  • GlobeNewswire

    Microbix Reports Record Results for Fiscal 2021

    Record Sales of $18.6 million, Record Net Earnings of $3.2 millionMISSISSAUGA, Ontario, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, reports results for its year and fourth quarter ended September 30, 2021 (“2021” and “Q4”), with record sales and earnings, plus progress upon its strategic goal of increasing the proportion of revenues derived from medical devices. Management Discussion 2021 revenues were up

  • GlobeNewswire

    Microbix Launches Multiplex Respiratory PCR-Test Control

    Helping Ensure Workflow Accuracy of Tests for COVID, Flu A, Flu B, and RSVMISSISSAUGA, Ontario, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces the expansion of its portfolio of Quality Assessment Products (“QAPs™”) to include single-unit swab-formatted controls that simultaneously support PCR tests for SARS-CoV-2 (“COVID”), Influenza A (“Flu A”), Influenza B (“Flu B”), and Respiratory Syncytial Vir